Biliary Atresia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Albireo Pharma, Mirum Pharma

The Biliary Atresia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Atresia pipeline products will significantly revolutionize the Biliary Atresia market dynamics.

DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Biliary Atresia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Biliary Atresia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Atresia Market Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Biliary Atresia Market Report:
• The Biliary Atresia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• DelveInsight estimates that in 2023, there were around 609 incident cases of Biliary Atresia across the 7MM. Among these, the US contributed approximately 56% of the cases, while 28% were reported in the EU4 and the UK combined, and 16% in Japan.
• Based on epidemiology model estimates, there were approximately 338 incident cases of biliary atresia in the US in 2023, with these numbers projected to rise by 2034.
• In 2023, approximately 17 cases were reported for Type I, 7 cases for Type II, and 315 cases for Type III. According to our estimates, these numbers are expected to fluctuate over the forecast period (2024-2034).
• In 2023, Germany reported approximately 34 cases of biliary atresia, with about 17 cases occurring in males and 18 in females.
• In 2023, the UK recorded approximately 19 cases of biliary atresia in males and 25 cases in females. According to DelveInsight's analysts, the total number of cases in both genders is expected to decline in the coming years, primarily due to a projected decrease in the country's population by 2034.
• In 2023, Japan reported 11 cases of Type I and 2 cases of Type II biliary atresia. DelveInsight's analysts indicate that Type III had the highest incidence, with 80 reported cases.
• Key Biliary Atresia Companies: Intercept Pharmaceuticals, Albireo Pharma, Mirum Pharmaceuticals, and others
• Key Biliary Atresia Therapies: Obeticholic Acid, BYLVAY, LIVMARLI, and others
• The Biliary Atresia epidemiology based on gender analyzed that Biliary Atresia is slightly more common in female infants

Biliary Atresia Overview
Biliary atresia is a rare, life-threatening condition in infants where the bile ducts, which carry bile from the liver to the gallbladder and small intestine, become blocked or absent. This blockage leads to a buildup of bile in the liver, causing liver damage and jaundice. If not treated promptly, biliary atresia can result in cirrhosis and liver failure. The most common treatment is a surgical procedure called the Kasai procedure, which aims to restore bile flow. In severe cases, a liver transplant may be necessary. Early diagnosis and treatment are crucial for improving outcomes.

Get a Free sample for the Biliary Atresia Market Report:
https://www.delveinsight.com/report-store/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Atresia Market
The dynamics of the Biliary Atresia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2020-2034.
"In October 2020, the United States Food and Drug Administration (USFDA) granted orphan drug status to Mirum Pharmaceuticals' LIVMARLI for the treatment of Biliary Atresia"

Biliary Atresia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Atresia Epidemiology Segmentation:
The Biliary Atresia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Biliary Atresia
• Prevalent Cases of Biliary Atresia by severity
• Gender-specific Prevalence of Biliary Atresia
• Diagnosed Cases of Episodic and Chronic Biliary Atresia

Download the report to understand which factors are driving Biliary Atresia epidemiology trends @ Biliary Atresia Epidemiological Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Atresia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched during the study period. The analysis covers Biliary Atresia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Atresia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Atresia Therapies and Key Companies
• Obeticholic Acid: Intercept Pharmaceuticals
• BYLVAY: Albireo Pharma
• LIVMARLI: Mirum Pharmaceuticals

To know more about Biliary Atresia treatment, visit @ Biliary Atresia Medications
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Atresia Market Drivers
• Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in Biliary Atresia
• The increasing prevalence of Biliary Atresia, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future.

Biliary Atresia Market Unmet Needs
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Biliary Atresia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Atresia Companies: Intercept Pharmaceuticals, Albireo Pharma, Mirum Pharmaceuticals, and others
• Key Biliary Atresia Therapies: Obeticholic Acid, BYLVAY, LIVMARLI, and others
• Biliary Atresia Therapeutic Assessment: Biliary Atresia current marketed and Biliary Atresia emerging therapies
• Biliary Atresia Market Dynamics: Biliary Atresia market drivers and Biliary Atresia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Atresia Unmet Needs, KOL's views, Analyst's views, Biliary Atresia Market Access and Reimbursement

Discover more about therapies set to grab major Biliary Atresia market share @ Biliary Atresia Treatment Landscape
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Biliary Atresia Market Report Introduction
2. Executive Summary for Biliary Atresia
3. SWOT analysis of Biliary Atresia
4. Biliary Atresia Patient Share (%) Overview at a Glance
5. Biliary Atresia Market Overview at a Glance
6. Biliary Atresia Disease Background and Overview
7. Biliary Atresia Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Atresia
9. Biliary Atresia Current Treatment and Medical Practices
10. Biliary Atresia Unmet Needs
11. Biliary Atresia Emerging Therapies
12. Biliary Atresia Market Outlook
13. Country-Wise Biliary Atresia Market Analysis (2020-2034)
14. Biliary Atresia Market Access and Reimbursement of Therapies
15. Biliary Atresia Market Drivers
16. Biliary Atresia Market Barriers
17. Biliary Atresia Appendix
18. Biliary Atresia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

22q11.2 Deletion Syndrome Pipeline https://www.delveinsight.com/report-store/biliary-atresia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"22q11.2 Deletion Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the 22q11.2 Deletion Syndrome market. A detailed picture of the 22q11.2 Deletion Syndrome pipeline landscape is provided, which includes the disease overview and 22q11.2 Deletion Syndrome treatment guidelines.

22q11.2 Deletion Syndrome Epidemiology https://www.delveinsight.com/report-store/biliary-atresia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's '22q11.2 Deletion Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted 22q11.2 Deletion Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.